Biggest Parkinson’s European drug trial gives hope to people living with Parkinson’s
bella - April 19th, 2017
200th Anniversary of World Parkinson’s Day – Tuesday 11 April, 2017
EMBARGOED TO TUESDAY 11 APRIL, 2017
With the 200th anniversary of World Parkinson’s Day on Tuesday 11 April, research and a new clinical trial conducted into the progressive neurological condition has given people living with Parkinson’s new levels of hope.
Respected French Professor David Devos who will be in Australia for a scientific symposium on World Parkinson’s Day is leading the largest clinical trial in Europe on a drug that may slow the progression of Parkinson’s and may allow people living with Parkinson’s a better quality of life.
Recent studies have identified excess iron levels in the brains of people living with Parkinson’s.
“Elevation of brain iron is one of the defining features of Parkinson’s and an overload of iron in the brain, causing the brain to ultimately “rust”, may be one of the possible causes of Parkinson’s,” said Devos.
Research has shown that the lowering of brain iron and redistributing it within the body with a drug which is already approved for clinical use, has slowed the progression of the condition.
The drug is now the basis of a large-scale European clinical trial led by Professor David Devos across 28 countries with 338 people living with Parkinson’s.
While this will not be a “cure” for Parkinson’s, early pilot studies of the drug in France and the United Kingdom indicate that reducing these excess iron levels in the brain may help slow the progression of Parkinson’s.
Slowing the progression of Parkinson’s will be good news to those living with the condition. It will mean being able to work longer and enjoy the things in life that are often taken for granted.
Results from the study will be available in 2019.
To commemorate the 200th anniversary of World Parkinson’s Day on Tuesday 11 April and to help draw the Parkinson’s community together, Devos will be visiting Australia to speak about this ground-breaking drug to Parkinson’s researchers and specialists.
While here, Devos will also be speaking to the broader Parkinson’s community on recent research and his clinical trial.
Currently, more than 27,000 Victorians and more than 80,000 Australians are living with Parkinson’s.
That translates to one in 350 Australian’s living with Parkinson’s, and a further 30 people are diagnosed each day.
2017 is the year to join a global community to #UniteForParkinsons aiming to raise unprecedented awareness of the condition and further the search for a cure.
All funds raised will help to continue ground breaking research into diagnosis, improved treatment and a cure for Parkinson’s
This year Parkinson’s Victoria has committed to raising $250,000 with community support to donate to research into Parkinson’s. This amount will be matched by research organisations so that a total of $500,000 can be invested in the search for a cure.